All Outputs (2)

CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds (2009)
Journal Article
Khan, A., Nicholson, G., McRobbie, G., Greenman, J., Pannecouque, C., Daelemans, D., Schols, D., De CLercq, E., Hubin, T. J., & Archibald, S. J. (2009). CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds. Antiviral research, 82(2), A59-A60. https://doi.org/10.1016/j.antiviral.2009.02.141

AMD3100 is a bis-azamacrocyclic compound that has been demonstrated to be a highly effective antagonist of the CXCR4 chemokine receptor. The two azamacrocyclic rings have been shown to interact with aspartate residues on the receptor via hydrogen bon... Read More about CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds.

Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes (2009)
Journal Article
Khan, A., Nicholson, G., McRobbie, G., Pannecouque, C., De Clercq, E., Ullom, R., Maples, D. L., Maples, R. D., Silversides, J. D., Hubin, T. J., Archibald, S. J., Madden, L., & Greenman, J. (2009). Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes. Journal of the American Chemical Society, 131(10), 3416-3417. https://doi.org/10.1021/ja807921k

A new copper(II) containing bis-macrocyclic CXCR4 chemokine receptor antagonist is shown to have improved binding properties to the receptor protein in comparison to the drug AMD3100 (Plerixafor, Mozobil). The interaction of the metallodrug has been... Read More about Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes.